Doctors may profit professionally or financially from administering an experimental therapy, but their first responsibility has traditionally been to the patient, not to the treatment. It is understood that the doctor must look out for (some would say 'protect') the patient, especially in the period before the efficacy of a treatment is proved. The possibility of personal gain must not color his
... [Show full abstract] or her recommendation about an experimental treatment. The establishment of a for-profit company that offers experimental treatments to those who can afford to underwrite the costs of development is a departure from this tradition. This approach, if widely adopted, will be of interest and possibly of concern, to the general public as well as the biomedical community. I will describe the early plans of the first company of this type to be established and then consider some of the issues raised by the development of this type of enterprise.